Navigation Links
SeraCare Life Sciences Sharpens Focus on Diagnostics Industry
Date:1/4/2013

Milford, MA (PRWEB) January 03, 2013

SeraCare Life Sciences, a portfolio company of Linden Capital Partners serving the in vitro diagnostics and clinical laboratory markets, has reorganized into three market-based commercial business units: IVD Research, IVD Processing and Clinical Laboratory. The new structure is designed to deliver greater insight into customer needs while streamlining business processes. In addition, SeraCare now has a complete senior management team, welcoming five new key executives to lead the Company’s commercial business units as well as operations, research and development, and quality organizations.

“Our industry is entering a period of great change as new diagnostics technologies enable an unprecedented level of personalized medicine,” said Charles Mamrak, CEO of SeraCare. “Our customers need our help in turning these changes into business opportunities. Allowing our customer-facing personnel to focus on a single, key market will make it easier for them to anticipate and meet these customers’ needs.”

To lead SeraCare to the next phase of its growth and focus on precision medicine, SeraCare welcomes five key executives:

Russell Garlick, Ph.D. serves as Chief Scientific Officer, focusing on expansion of the Company’s R&D organization and product development pipeline. Dr. Garlick has worked on the development, regulatory approval and launch of a variety of technologies and assays, including an HIV AIDS patient management program, molecular genomics technologies and HIV drug discovery systems. Prior to joining SeraCare, he was co-founder of Life Sciences Group and also served as CEO and CTO of Protein Forest, Inc. Dr. Garlick also held executive R&D positions at PerkinElmer Life Sciences and DuPont NEN Life Sciences. Dr. Garlick has both a Ph.D. and M.S. in Biomedical Sciences, Medicinal Chemistry from the Barnett Institute at Northeastern University as well as a B.S. in Biology from University of Massachusetts at Lowell.

Cheri Walker, Ph.D. has joined as Chief Commercial Officer and will act as the head of the IVD Research and Clinical Laboratory business units in addition to overseeing corporate development activities. Prior to this position, Dr. Walker consulted with private equity firms and both diagnostic and life science tools companies on marketing, strategy and corporate development activities. In the past, she has held senior level corporate development, marketing and business unit leadership roles at Charles River Laboratories, QIAGEN and Invitrogen (now Life Technologies) and was the stock analyst covering the Life Science Tools companies for Deutsche Bank. Dr. Walker holds a Ph.D. in Human and Molecular Genetics from Baylor College of Medicine and a B.A. in Biology from Swarthmore College.

Ann McCormick is SeraCare’s new Chief Operating Officer. She brings extensive life science industry experience in manufacturing, laboratory and executive roles. Most recently, she co-founded and managed SeraMetrix Corporation where she was involved with developing and manufacturing protein biomarkers for oncology and autoimmune applications. Prior to that role, Ms. McCormick worked with Invitrogen (now Life Technologies) for over 12 years where she held numerous manufacturing and operational leadership positions. As Vice President of Manufacturing Operations, she managed the Company’s global production sites including GMP compliant facilities. Before Life Technologies, Ms. McCormick was a Senior Scientist with Beckman where she helped developed recombinant proteins for HIV assays. She holds an M.S. in Microbiology from Indiana State University and a B.S. in Biology from Christopher Newport College.

Joe Kozma joins SeraCare as Vice President of IVD Process Solutions. Previously, Mr. Kozma held executive positions at Serologicals and Millipore. He was also co-founder of Intergen, a manufacturer of biological and recombinant reagents for research and manufacturing of biopharmaceutical and diagnostic products. Mr. Kozma brings rich experience working with IVD manufacturers and will build and manage the IVD Process Solutions group to better meet the needs of these organizations. Mr. Kozma holds a Bachelor of Science degree from Ball State University.

Lisa Alexander serves as SeraCare’s Vice President, Quality and Regulatory where she will be focused on driving SeraCare’s mission to meet or surpass our customers’ quality expectations, regulatory requirements and industry standards. She brings significant experience leading quality and regulatory teams in the life sciences and diagnostic industries including her most recent role as VP, Quality and Regulatory Affairs at Xcellerex (GE Healthcare). Prior to Xcellerex, she was Director, Corporate QA/RA at Millipore Corporation and held leadership roles in Quality at Amgen, GTC Biotherapeutics and BioReliance. Ms. Alexander holds an M.S. in Environmental and Occupational Health and Safety from Anna Maria College, an M.B.A. from Northeastern University and a B.S. in Bio-Psychology from Tufts University.

About SeraCare Life Sciences, Inc.
SeraCare partners with diagnostics researchers, IVD manufacturers and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality controls, research panels, SeraCon® processed biological materials, specialty human blood products and characterized disease state materials. SeraCare helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging technologies for molecular diagnostics, next generation sequencing and companion diagnostics. For more information, visit http://www.seracare.com.

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden currently has investments in middle market platforms in the products, distribution, and services segments of healthcare. For additional information about Linden, please refer to the firm's website at http://www.lindenllc.com.

# # #

Read the full story at http://www.prweb.com/releases/2013/1/prweb10290239.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SeraCare Shareholders Approve Acquisition by Linden Capital Partners
2. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
3. Breakthrough Book From GLS Sciences Ends Blood Sugar Abuse in Time For The Holidays
4. 1DegreeBio Expands its Product Review Platform Across Life Sciences
5. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
6. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
7. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
8. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
9. Marrone Bio Innovations’ CEO to Address European Biopesticide Industry at Informa Life Sciences Biopesticides Conference
10. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
11. A leading Massachusetts-based IT and Life Sciences staffing and consulting firm has opened two new offices in the Ohio Valley
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016  Spherix Incorporated (Nasdaq: SPEX ) -- an ... monetization of intellectual property, today provided an update on ... Northern District of Texas and ... Inter Partes Re-examination ("IPR") proceedings that VTech ... IPR was initiated on only certain claims of two ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
(Date:2/3/2016)... Pa. , Feb. 3, 2016  Discovery ... company focused on developing aerosolized KL4 surfactant therapies ... of Directors has approved an inducement award as ... Fraser , its newly appointed President and Chief ... Board,s Compensation Committee on February 1, 2016 and ...
(Date:2/3/2016)... and HOLLISTON, Mass., Feb. 3, 2016 Harvard ... a biotechnology company developing bioengineered organ implants for ... today announced that CEO Jim McGorry , ... Investor Conference on Tuesday, February 9, 2016 ... York City . HART,s presentation will be ...
Breaking Biology Technology:
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
(Date:2/1/2016)... , February 1, 2016 Rising ... to drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new ... market size through 2020   ... coupled with new technological advancements to drive global touchfree ...
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
Breaking Biology News(10 mins):